8-K: Masimo Announces Preliminary 2024 Results and Provides 2025 Guidance, Exceeding Expectations

Masimo reported preliminary full-year 2024 healthcare revenue of $1.395 billion, a 10% constant currency increase, and provided 2025 guidance with improved non-GAAP operating margin targets.

Summary

• Masimo announced preliminary financial results for the fourth quarter and full year 2024, along with full-year 2025 guidance.
• The company expects full-year 2024 healthcare revenue to be approximately $1.395 billion, representing a 10% growth on a constant currency basis.
• Non-healthcare revenue for 2024 is expected to be approximately $699 million, a 9% decline on a constant currency basis.
• Consolidated revenue for 2024 is expected to be $2.094 billion, a 3% increase on a constant currency basis.
• Non-GAAP earnings per diluted share for 2024 are expected to be more than $4.10, which is at the high end of the prior guidance range.
• For 2025, Masimo projects healthcare revenue between $1.500 billion and $1.530 billion, representing 8% to 11% growth on a constant currency basis.
• The company anticipates a non-GAAP operating profit between $398 million and $406 million for 2025, with non-GAAP operating margins of at least 26.5%.
• Non-GAAP earnings per diluted share for 2025 are projected to be between $4.90 and $5.10.
• Masimo is in the process of separating its Sound United business, and its financial impact will be excluded from non-GAAP measures starting in 2025.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong healthcare revenue growth, improved margin targets, and a strategic focus on the core business. The exit of the non-core consumer audio business is also viewed positively. However, the decline in non-healthcare revenue and the risks associated with the business separation temper the overall sentiment slightly.

Positives

• Masimo's healthcare revenue growth is strong, with a 10% increase on a constant currency basis for 2024.
• The company's non-GAAP earnings per share exceeded expectations, reaching the high end of the prior guidance range.
• The increase in the 2025 non-GAAP operating margin target to at least 26.5% indicates improved profitability.
• The company's focus on the professional healthcare market is expected to drive consistent growth and margin expansion.
• Masimo has a large installed base of technology boards and monitors, creating a recurring revenue model.
• The company's differentiated technology and intellectual property create barriers to entry and significant switching costs.
• Masimo has a strong track record of innovation and is a leader in non-invasive monitoring.
• The exit of the Sound United business will allow the company to focus on its core healthcare business.

Negatives

• Non-healthcare revenue declined by 9% on a constant currency basis for 2024.
• The company is in the process of exiting the Sound United business, which may involve costs and disruptions.
• The company's non-GAAP financial measures exclude certain items, which may not reflect all costs associated with operations.

Risks

• The company's dependence on Masimo SET and Masimo rainbow SET products and technologies for substantially all of its revenue.
• The risk of intellectual property claims and the highly competitive nature of the markets in which Masimo operates.
• The potential failure to continue developing innovative products and technologies.
• The risk of not successfully integrating acquired businesses or expanding into new markets.
• The possibility of product liability claims and the failure to obtain expected returns from intangible assets.
• The uncertainty of the expected financial performance of Masimo prior to and following completion of any potential separation of the consumer business.
• The potential for negative effects of the announcement or pendency of any such potential separation on the market price of Masimo's securities.
• The risk of evolving legal, regulatory and tax regimes and changes in general economic conditions.

Future Outlook

Masimo expects continued growth in its healthcare business, with a focus on innovation and operational efficiencies. The company anticipates significant margin expansion and is targeting best-in-class medtech margin profile. The exit of the Sound United business will allow the company to focus on its core professional healthcare market.

Management Comments

• Management believes that adjustments for certain items assist investors in making comparisons of period-to-period operating results.
• Management believes that these items are not indicative of the company's on-going core operating performance.
• Management uses non-GAAP financial measures to better understand and evaluate the business.
• Management is focused on delivering best-in-class growth, driving innovation, and improving operational efficiencies.
• Management is strategically aligning the organization to drive sustainable long-term growth.

Industry Context

Masimo's focus on non-invasive monitoring aligns with the broader trend in healthcare towards less invasive and more patient-friendly technologies. The company's strong position in pulse oximetry and its expansion into other monitoring areas position it well in the competitive medical device market. The exit of the consumer audio business reflects a strategic shift towards the core healthcare market, which is a common move for companies seeking to streamline operations and focus on their strengths.

Comparison to Industry Standards

• Masimo's 10% constant currency growth in healthcare revenue for 2024 is strong compared to the overall medical device industry, which typically sees mid-single-digit growth.
• The company's non-GAAP operating margin target of at least 26.5% for 2025 is competitive with leading medtech companies such as Medtronic and Stryker, which often have operating margins in the mid-to-high 20s.
• Masimo's focus on recurring revenue through consumables and services is a common strategy in the medical device industry, similar to companies like Intuitive Surgical with their da Vinci surgical system.
• The company's large installed base of 2.6 million technology boards and monitors is a significant advantage, creating a barrier to entry for competitors.
• Masimo's innovation in non-invasive monitoring is comparable to other companies in the space, such as Philips and GE Healthcare, but Masimo has a strong focus on pulse oximetry and related technologies.

Management Changes

Legal Proceedings

• The company has been engaged in various legal proceedings against Apple since January 2020.

Stakeholder Impact

• Shareholders are likely to react positively to the strong healthcare revenue growth and improved margin targets.
• Employees may experience changes due to the exit of the Sound United business and organizational restructuring.
• Customers will continue to benefit from Masimo's innovative monitoring technologies.
• Suppliers may be impacted by changes in the company's product portfolio and manufacturing footprint.
• Creditors will likely view the company's financial performance positively.

Next Steps

• The company will conduct its fourth quarter 2024 investor conference call on Tuesday, February 25, 2025.
• Masimo will continue to focus on its core healthcare business and drive innovation.
• The company will continue to work towards the exit of the Sound United business in the first half of 2025.
• Masimo will continue to optimize its manufacturing footprint in Malaysia and reduce product costs.

Key Dates

Keywords

non-invasive monitoring, healthcare technology, pulse oximetry, patient monitoring, medical devices, revenue growth, operating margin, non-GAAP, Sound United, innovation